<DOC>
	<DOCNO>NCT00853996</DOCNO>
	<brief_summary>This phase II trial study well acolbifene work prevent cancer premenopausal woman high risk breast cancer . Chemoprevention use certain drug keep cancer forming . The use acolbifene may stop cancer grow come back .</brief_summary>
	<brief_title>Acolbifene Preventing Cancer Premenopausal Women High Risk Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine effect six month acolbifene 20 mg/day Ki-67 high risk premenopausal woman baseline hyperplasia +/- atypia Ki-67 positivity &gt; = 2 % .. SECONDARY OBJECTIVES : I . To determine effect six month acolbifene 20 mg/day mammographic breast density high risk premenopausal woman . II . To determine effect six month acolbifene 20 mg/day serum level follicular phase bioavailable estradiol , luteal phase progesterone , testosterone , fast IGF-1/IGFBP-3 . III . To determine effect six month acolbifene 20 mg/day epithelial cell cytomorphology molecular marker ER , PgR , pS2 . IV . To determine effect six month acolbifene marker cardiovascular risk ( C-reactive protein , functional AntiThrombin III , fast lipid profile ) bone turnover marker associate bone mineral density gain loss ( serum osteocalcin N-telopeptide crosslinks ) . V. To assess increase report hot flash , menstrual cycle irregularity , pelvic pain , musculoskeletal complaint , fatigue baseline . OUTLINE : Patients receive oral acolbifene hydrochloride daily 6 month absence unacceptable toxicity . Patients undergo symptom assessment ( hot flash , menstrual abnormality , pelvic pain , muscle joint pain , fatigue ) baseline , 6-8 week , monthly 6 month , 2 week completion study treatment . Patients undergo random periareolar fine needle aspiration day 1-10 menstrual cycle baseline 6 month . Patients also undergo blood sample collection day 1-10 day 20-24 menstrual cycle baseline 6 month . Samples take day 1-10 menstrual cycle analyze Ki-67 expression , cytomorphology , molecular marker ( estrogen receptor , progesterone receptor , pS2 expression ) , bioavailable estradiol level . Samples take day 20-24 menstrual cycle analyze progesterone , testosterone , IGF-1 , IGFBP-3 , lipid profile , bone-turnover marker ( osteocalcin N-telopeptide crosslinks ) , C-reactive protein , functional antithrombin III . After completion study treatment , patient follow 2 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Gail risk &gt; = 1.7 % and/or relative risk &gt; = 3 time 5year age group Premenopausal More 6 month since initiate discontinue oral contraceptive At increase risk breast cancer , indicate &gt; = 1 follow risk factor : BRCA1/2 mutation characterize deleterious uncertain significance Prior atypical ductal hyperplasia , ductal carcinoma situ , lobular carcinoma situ Prior random periareolar fine needle aspiration ( RPFNA ) show atypical hyperplasia Family history consistent hereditary breast cancer , indicate 1 follow criterion : &gt; = 4 relative breast cancer &gt; = 2 relative diagnose breast cancer â‰¤ 50 year age Breast ovarian cancer diagnose relative No suspicion breast cancer baseline mammogram perform day 110 menstrual cycle within 3 month prior screen baseline RPFNA Exhibits hyperplasia without atypia ( Masood score &gt; = 14 ) &gt; = 500 cell AND Ki67 positivity &gt; = 2 % RPFNA perform within 6 month prior initiation study drug Estimated visual mammographic breast density category &gt; = 5 % mammogram perform within 6 month prior initiation study drug Has regular menstrual cycle ( 21 35 day ) unless use extended regimen oral contraceptive contraceptive device ( e.g. , Mirena IUD ) Values metabolic profile blood count within normal limit Absolute granulocyte count &gt; 1,000/mm^3 Platelets &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL Bilirubin &lt; 2.0 mg/dL AST &lt; 2 time upper limit normal ( ULN ) Albumin &gt; 3.0 g/dL Creatinine &lt; 1.5 mg/dL Alkaline phosphatase &lt; 2 time ULN Concurrent hormonal contraceptive allow provided patient remain hormonal regimen 3 month prior baseline aspiration completion study treatment Fertile patient must use effective contraception 3 month completion study treatment Willing ingest recommend dose calcium vitamin D premenopausal bone health ( 1,200 mg calcium 800 IU vitamin D daily ) Negative pregnancy test prior receive study agent Exclusion Criteria pregnant nursing nursing within past 6 month Known osteoporosis severe osteopenia ( Tscore 2 bad DEXA ) History symptomatic endometriosis pelvic pain , poorly control migraine , hot flash History deep venous thrombosis History allergic reaction attribute compound similar chemical biological composition study agent Other condition concurrent illness , opinion investigator , would make patient poor candidate RPFNA Less 1 year since prior use aromatase inhibitor ( e.g. , anastrozole , exemestane , letrozole ) selective estrogen receptor modulators ( e.g. , tamoxifen citrate , raloxifene , arzoxifene hydrochloride ) Other concurrent chemopreventive agent Concurrent anticoagulant Other concurrent investigational agent Bilateral breast implant</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>